Norgestrel is a lipid of Sterol Lipids (ST) class. Norgestrel is associated with abnormalities such as Acne, Deep Vein Thrombosis, Thromboembolism, Activated Protein C Resistance and Hydrometra. The involved functions are known as Thrombosis, Aquatic environment, Venous Thrombosis, Thrombus and Inspiration function. Norgestrel often locates in Glial. The associated genes with Norgestrel are Genes, Reporter. The related lipids are Estranes.
To understand associated biological information of Norgestrel, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Norgestrel is suspected in Thromboembolism, Acne, Deep Vein Thrombosis, Activated Protein C Resistance, Hydrometra, Withdrawal bleeding and other diseases in descending order of the highest number of associated sentences.
| Disease | Cross reference | Weighted score | Related literature |
|---|
We collected disease MeSH terms mapped to the references associated with Norgestrel
| MeSH term | MeSH ID | Detail |
|---|---|---|
| Body Weight | D001835 | 333 associated lipids |
| Osteosarcoma | D012516 | 50 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Gynecomastia | D006177 | 6 associated lipids |
| Venous Thrombosis | D020246 | 11 associated lipids |
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
| Location | Cross reference | Weighted score | Related literatures |
|---|
| Function | Cross reference | Weighted score | Related literatures |
|---|
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
| Gene | Cross reference | Weighted score | Related literatures |
|---|
There are no associated biomedical information in the current reference collection.
| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Gemzell-Danielsson K et al. | A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg) in postmenarcheal adolescents. | 2016 | Contraception | pmid:26872720 |
| Festin MP et al. | A prospective, open-label, single arm, multicentre study to evaluate efficacy, safety and acceptability of pericoital oral contraception using levonorgestrel 1.5 mg. | 2016 | Hum. Reprod. | pmid:26830816 |
| Zhang D et al. | Association between knowledge about levonorgestrel emergency contraception and the risk of ectopic pregnancy following levonorgestrel emergency contraception failure: a comparative survey. | 2016 | Pharmacoepidemiol Drug Saf | pmid:26748685 |
| Samson M et al. | Progestin and breast cancer risk: a systematic review. | 2016 | Breast Cancer Res. Treat. | pmid:26700034 |
| Leung VW et al. | Population-based evaluation of the effectiveness of two regimens for emergency contraception. | 2016 | Int J Gynaecol Obstet | pmid:26969148 |
| Lobo Abascal P et al. | Differences in reporting Pearl Indices in the United States and Europe: Focus on a 91-day extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation. | 2016 | Eur J Contracept Reprod Health Care | pmid:26115381 |
| Maybin JA and Critchley HO | Medical management of heavy menstrual bleeding. | 2016 | Womens Health (Lond) | pmid:26695687 |
| Levonorgestrel-Releasing Intrauterine System (52 mg) for Idiopathic Heavy Menstrual Bleeding: A Health Technology Assessment. | 2016 | Ont Health Technol Assess Ser | pmid:27990196 | |
| Motegi E et al. | Levonorgestrel-releasing intrauterine system placement for severe uterine cervical stenosis after conization: two case reports. | 2016 | J Med Case Rep | pmid:26960298 |
| Rowe P et al. | Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A. | 2016 | Contraception | pmid:26916172 |